フィブリノゲン濃度投与後の血栓凝固度における用量依存的変化: 遡及的観察研究
Stanislaw Vander Zwaag1, Imre Kukel1, Kinga Towarek-Nocon2
1Insitute of Cardiac Anesthesiology, Faculty of Medicine and Heart Center, TUD Dresden University of Technology, Dresden, Germany.
Journal of cardiothoracic and vascular anesthesia
|August 22, 2025
まとめ
フィブリノゲン濃縮剤の投与は,心臓手術患者の凝固強度の変化を効果的に予測します. 体重に基づく投与量は,凝固の固さ (A5) と相関し,低線維生性血症の管理に役立ちます.
科学分野:
- 麻酔科
- 血液学
- 診療所での診断
背景:
- 心臓外科では 粘着弾性点検が不可欠です
- FIBTEM測定ガイドラインは,出血を最小限に抑えるために,最大限の凝固度を目標にすることを推奨しています.
- これらの目標を達成するための最適な線維素濃縮物 (FC) の用量は明確に定義されていません.
研究 の 目的:
- 心臓外科手術の患者で5分 (A5) 後のFCと凝固強さの投与反応関係を分析する.
- 術後の低線維原血症に対するA5の予測値を評価する.
主な方法:
- 高等学術心臓病院での遡及的観察研究
- 2022年5月から2024年8月の間に180人の心臓手術患者を含む.
- 手術中の回転性血栓測定 (ROTEM) データと凝固因子投与を分析した.
主要な成果:
- 線形回帰では,体重に基づくFC投与とA5の変化との間に強い相関が示された.
- 体重ベース (総量,理想量,痩身量) に応じて,FCの10 mg/kg増量でA5が上昇した.
- A5 ≤12 mm 精確に予測された低線維生性血症 (77%の感度,94%の特異性).
結論:
- 体重に基づくフィブリノゲン投与は,A5の平均変化の予測を可能にします.
- 総体重,理想体重,痩身体重は,FC投与で比較可能な相関係数を示した.
- A5測定は,このコホートにおけるハイポフィブリノゲネミアの重要な予測指標である.
関連する概念動画
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K


